A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

Previous results suggest that GEM affects 5-fluorouracil (5-FU) metabolism and pharmacokinetics in cancer patients, while combined with oxaliplatin, levo-folinic acid, and 5-FU (GOLF regimen), at doses achievable in cancer patients, determines high cytotoxic and proapoptotic antitumour activity in c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Correale, P, Messinese, S, Caraglia, M, Marsili, S, Piccolomini, A, Petrioli, R, Ceciarini, F, Micheli, L, Nencini, C, Neri, A, Vuolo, G, Guarnieri, A, Abbruzzese, A, Prete, S D, Giorgi, G, Francini, G
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2004
Subjects:	Clinical
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2409742/ https://ncbi.nlm.nih.gov/pubmed/15150625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601783
Tags:	Add Tag No Tags, Be the first to tag this record!

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

Similar Items